Atlas Trials

Burosumab for Fibroblast Growth Factor-23 Mediated Hypophosphatemia in Fibrous Dysplasia

Clinical trial NCT05509595 · COMPLETED

Trial details

NCT number
NCT05509595
Sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Fibrous Dysplasia Of Bone
Start date
2022-12-07
Primary completion
2024-11-18
Enrollment
12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.